Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2018.4005
Abstract: Importance Chimeric and murine anti-GD2 antibodies are active against neuroblastoma, but the development of neutralizing antibodies can compromise efficacy. To decrease immunogenicity, hu3F8, a humanized anti-GD2 antibody, was constructed. Objective To find the maximum-tolerated dose… read more here.
Keywords: trial; anti gd2; antibody; cycle ... See more keywords
A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors
Sign Up to like & getrecommendations! Published in 2020 at "mAbs"
DOI: 10.1080/19420862.2020.1773751
Abstract: ABSTRACT Hu14.18K322A is a humanized anti-GD2 monoclonal antibody with a single point mutation that reduces complement-mediated cytotoxicity, with a maximum tolerated dose (MTD) of 60 mg/m2 daily for 4 days in children with recurrent/refractory neuroblastoma.… read more here.
Keywords: humanized anti; anti gd2; schedule; patients osteosarcoma ... See more keywords
PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO
Sign Up to like & getrecommendations! Published in 2017 at "OncoImmunology"
DOI: 10.1080/2162402x.2017.1343775
Abstract: ABSTRACT Immunotherapy with anti-GD2 antibody (Ab) ch14.18/CHO is effective for treatment of high-risk neuroblastoma (NB) patients and is mainly based on GD2-specific Ab-dependent cellular cytotoxicity (ADCC). Strategies to further enhance the efficacy are important and… read more here.
Keywords: anti gd2; cho; blockade; ch14 cho ... See more keywords
First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000002488
Abstract: Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells,… read more here.
Keywords: sarcoma; gd2; like sarcoma; metastatic ewing ... See more keywords
Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-004399
Abstract: Background Anti-GD2 monoclonal antibody immunotherapy has significantly improved the overall survival rate for high-risk neuroblastoma patients. However, 40% of patients fail to respond or develop resistance to treatment, and the molecular mechanisms by which this… read more here.
Keywords: derived sevs; immunotherapy; anti gd2; neuroblastoma ... See more keywords
Abstract 5115: Novel humanized anti-GD2 antibody inhibits GD2-mediated immunosuppression by targeting GD2+ breast cancer stem-like cells
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5115
Abstract: Background: Breast cancer stem-like cells (BCSCs) are reported to be a major contributing factor for tumor growth and chemotherapy resistance in triple-negative breast cancer (TNBC). We reported that the disialoganglioside GD2 is highly expressed on… read more here.
Keywords: cell; gd2; breast cancer; anti gd2 ... See more keywords
Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/refractory high-risk neuroblastoma (HR-NB).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.10543
Abstract: 10543Background: NB is a rare cancer but represents the most common extracranial solid tumor of childhood. Most HR-NB patients present with or develop metastatic disease typically in bone or bone m... read more here.
Keywords: new generation; generation anti; gd2 monoclonal; naxitamab new ... See more keywords
Spinal nerve roots contrast enhancement following anti-GD2 antibody therapy in neuroblastoma
Sign Up to like & getrecommendations! Published in 2018 at "Neurology"
DOI: 10.1212/wnl.0000000000005483
Abstract: A 2-year-old boy with grade IV neuroblastoma presented with acute neurogenic bladder and hyposthenia after 2 weeks of treatment with anti-ganglioside-GD2 antibody (GD2-Ab). Spinal MRI findings are shown in the figure. On nerve conduction studies,… read more here.
Keywords: anti gd2; contrast enhancement; gd2 antibody; spinal nerve ... See more keywords
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.15073
Abstract: Aromatase is a critical enzyme in the irreversible conversion of androgens to oestrogens, with inhibition used clinically in hormone-dependent malignancies. We tested the hypothesis that targeted aromatase inhibition in an aggressive brain cancer called glioblastoma… read more here.
Keywords: inhibitor; ch14 cho; anti gd2; gbm ... See more keywords
Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular Immunotherapy
Sign Up to like & getrecommendations! Published in 2023 at "AntiCancer Research"
DOI: 10.21873/anticanres.16409
Abstract: Background/Aim: Using the tyrosine hydroxylase (TH)-MYCN mouse neuroblastoma (NB) model, we have previously reported the accumulation of mouse mesenchymal stem cells (mMSCs) on tumors in vivo and the antitumor effect of mMSCs transfected with a… read more here.
Keywords: gd2; gd2 mscs; anti gd2; gd2 antibody ... See more keywords
Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13061264
Abstract: Simple Summary The anti-tumor activity of anti-GD2 monoclonal antibodies (mAbs) have been demonstrated by the capacity to mediate immunological cytotoxicity but also through direct cell death induction. Recently, studies with anti-GD2 mAbs for high-risk (HR)-neuroblastoma… read more here.
Keywords: gd2; immunotherapy; anti gd2; high risk ... See more keywords